If you enjoy intimate al fresco dining on the patio with your partner or catching up with a friend on your balcony, a great ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Soon after Borzelleca's paper was published in a scientific journal, Food and Chemical Toxicology, the FDA examined the data his team had collected and reached its own conclusion: that the dye caused ...